Brief: Glycomimetics Announces Continuation Of Phase 3 Study Of E-Selectin Antagonist Uproleselan
15/02/2023 14:04
Feb 15 (Reuters) - GlycoMimetics Inc GLYC.O :
* GLYCOMIMETICS ANNOUNCES CONTINUATION OF PHASE 3 STUDY OF
E-SELECTIN ANTAGONIST UPROLESELAN IN RELAPSED/REFRACTORY AML TO
ORIGINALLY PLANNED FINAL ANALYSIS FOLLOWING INTERIM ANALYSIS BY
INDEPENDENT DATA MONITORING COMMITTEE
* GLYCOMIMETICS INC - COMPANY RAISED $32.9 MILLION NET
PROCEEDS
VIA ATM FACILITY, EXTENDING CASH RUNWAY INTO Q4 2024
* GLYCOMIMETICS INC - PROCEEDS ARE EXPECTED TO EXTEND
COMPANY'S
CASH RUNWAY INTO Q4 OF 2024
* GLYCOMIMETICS INC - FINAL SURVIVAL EVENT TRIGGER EXPECTED
WITHIN
FIRST HALF OF 2024 FOR E-SELECTIN ANTAGONIST UPROLESELAN IN
RELAPSED/REFRACTORY AML
Source text for Eikon: ID:nBw4VyGZSa
Further company coverage: GLYC.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering